Somatostatin, estrogen, and polycystic liver disease

Gastroenterology

Volumn 145, Issue 2, 2013, Pages 279-282

  Everson, Gregory T ^a   Helmke, Steve M ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; ESTROGEN; OCTREOTIDE; PLACEBO; SOMATOSTATIN DERIVATIVE;

ABSENCE OF SIDE EFFECTS; DRUG INDICATION; GENE MUTATION; HUMAN; KIDNEY POLYCYSTIC DISEASE; LIVER POLYCYSTIC DISEASE; LIVER WEIGHT; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 84880604255     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2013.06.025     Document Type: Editorial

References (12)

1. T.J. Gevers, J. Inthout, and A. Caroli Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data Gastroenterology 145 2013 357 365
2. G.T. Everson, S.M. Helmke, and B. Doctor Advances in management of polycystic liver disease Exp Reviews Gastroenterol Hepatol 2 2008 563 576
3. T.V. Masyuk, A.I. Masyuk, and V.E. Torres Gevers. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3′, 5′-cyclic monophosphate Gastroenterology 132 2007 1104 1116
4. L. Van Keimpema, F. Nevens, and R. Vanslembrouck Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial Gastroenterology 137 2009 1661 1668
5. M. Chrispijn, F. Nevens, and T.J.G. Gevers The long-term outcome of patient with polycystic liver disease treated with lanreotide Aliment Pharmacol Ther 35 2012 266 274
6. A. Caroli, L. Antiga, and M. Cafaro Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide Clin J Am Soc Nephrol 5 2010 783 789
7. M.C. Hogan, T.V. Masyuk, and L.J. Page Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease J Am Soc Nephrol 21 2010 1052 1061
8. M.D. Hogan, T.V. Masyuk, and L. Page Somatostatin analog therapy for severe polycystic liver disease: results after 2 years Nephrol Dial Transplant 27 2012 3532 3539
9. T.V. Masyuk, B.N. Radtke, and A.J. Stroope Pasireotide is more effective that octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver disease Hepatology 2012 http://dx.doi.org/10.1002/hep.26140 [Epub ahead of print]
10. Q. Qian, H. Du, and B.F. King Sirolimus reduces polycystic liver volume in APKD patients J Am Soc Nephrol 19 2008 631 638
11. M. Chrispijn, and J.P.H. Drenth Everolimus and long acting octreotide as a volume reducing treatment of polycystic liver (ELATE): study protocol for a randomized controlled trial BMC Trials 12 2011 246 254
12. M. Chrispijn, T.J. Gevers, and J.C. Hol Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: Results from a randomized controlled trial J Hepatol 2013 http://dx.doi.org/10.1016/j. jhep.2013.03.004 [Epub ahead of print]